US2013018176A1PendingUtilityA1

Methods of producing hybridomas and monoclonal antibodies and antibodies produced thereby

Assignee: AMGEN INCPriority: Feb 2, 2007Filed: Sep 14, 2012Published: Jan 17, 2013
Est. expiryFeb 2, 2027(~0.5 yrs left)· nominal 20-yr term from priority
A61P 9/10A61P 7/00A61P 7/06A61P 9/00A61P 43/00A61P 3/10A61P 31/18A61P 31/04A61P 35/00A61P 31/12A61P 29/00A61P 31/14A61P 3/12A61P 1/16A61P 1/04A61P 13/12A61P 1/18C07K 2317/21C12N 2310/111C07K 2317/56C12N 2310/53C07K 2317/92G01N 33/74C07K 14/575C12N 2310/14C07K 2317/34A61K 39/3955A61K 38/1816C12N 15/1136C07K 16/26C07K 2317/565A61K 2039/505
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are a method of producing a hybridoma, a method of making an antibody involving the hybridoma, and an antibody made by the method.

Claims

exact text as granted — not AI-modified
1 . A method of producing a hybridoma, comprising:
 (a) inoculating a mouse by subcutaneous, intradermal, or intramuscular injection with a recombinant adenoviral vector that comprises a gene encoding a protein of interest;   (b) isolating B-cells from the mouse about 10 days post-inoculation;   (c) fusing the isolated B-cells with mouse myeloma cells to produce a plurality of hybridomas;   (d) identifying a hybridoma from (c) that produces a monoclonal antibody that specifically binds the protein of interest.   
     
     
         2 . The method of  claim 1 , wherein the mouse is a C57B1/6 mouse or non-obese diabetic (NOD) mouse. 
     
     
         3 . A method of making an antibody, comprising the method of  claim 1 , and further comprising isolating the antibody from the hybridoma of (d). 
     
     
         4 . The method of  claim 3 , further comprising producing the antibody by recombinant expression of its amino acid sequence. 
     
     
         5 . An antibody made by the method of  claim 3  or  claim 4 .

Join the waitlist — get patent alerts

Track US2013018176A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.